BACKGROUND: The skeletal protein osteocalcin is gamma-carboxylated by vitamin K. High serum uncarboxylated osteocalcin reflects low vitamin K status. In vitro and animal studies indicate that high uncarboxylated osteocalcin is associated with reduced insulin resistance. However, associations between osteocalcin and measures of insulin resistance in humans are less clear. OBJECTIVE: Our aim was to examine cross-sectional and longitudinal associations between circulating forms of osteocalcin (total, uncarboxylated, and carboxylated) and insulin resistance in older men and women. DESIGN: Cross-sectional associations between serum measures of total osteocalcin, carboxylated osteocalcin, and uncarboxylated osteocalcin and insulin resistance were examined in 348 nondiabetic men and women (mean age: 68 y; 58% female) by using the homeostasis model assessment of insulin resistance (HOMA-IR). Associations between each form of osteocalcin at baseline and 3-y change in HOMA-IR were examined in 162 adults (mean age: 69 y; 63% female) who did not receive vitamin K supplementation. RESULTS: Lower circulating uncarboxylated osteocalcin was not associated with higher HOMA-IR at baseline or at 3-y follow-up. Those in the lowest tertiles of total osteocalcin and carboxylated osteocalcin at baseline had higher baseline HOMA-IR (P = 0.006 and P = 0.02, respectively). The concentration of carboxylated osteocalcin at baseline was inversely associated with a 3-y change in HOMA-IR (P = 0.002). CONCLUSIONS: In older adults, circulating uncarboxylated osteocalcin was not associated with insulin resistance. In contrast, elevated carboxylated osteocalcin and total osteocalcin were associated with lower insulin resistance, which supports a potential link between skeletal physiology and insulin resistance in humans. The role of vitamin K status in this association remains unclear and merits further investigation. This trial is registered at clinicaltrials.gov as NCT00183001.
BACKGROUND: The skeletal protein osteocalcin is gamma-carboxylated by vitamin K. High serum uncarboxylated osteocalcin reflects low vitamin K status. In vitro and animal studies indicate that high uncarboxylated osteocalcin is associated with reduced insulin resistance. However, associations between osteocalcin and measures of insulin resistance in humans are less clear. OBJECTIVE: Our aim was to examine cross-sectional and longitudinal associations between circulating forms of osteocalcin (total, uncarboxylated, and carboxylated) and insulin resistance in older men and women. DESIGN: Cross-sectional associations between serum measures of total osteocalcin, carboxylated osteocalcin, and uncarboxylated osteocalcin and insulin resistance were examined in 348 nondiabetic men and women (mean age: 68 y; 58% female) by using the homeostasis model assessment of insulin resistance (HOMA-IR). Associations between each form of osteocalcin at baseline and 3-y change in HOMA-IR were examined in 162 adults (mean age: 69 y; 63% female) who did not receive vitamin K supplementation. RESULTS: Lower circulating uncarboxylated osteocalcin was not associated with higher HOMA-IR at baseline or at 3-y follow-up. Those in the lowest tertiles of total osteocalcin and carboxylated osteocalcin at baseline had higher baseline HOMA-IR (P = 0.006 and P = 0.02, respectively). The concentration of carboxylated osteocalcin at baseline was inversely associated with a 3-y change in HOMA-IR (P = 0.002). CONCLUSIONS: In older adults, circulating uncarboxylated osteocalcin was not associated with insulin resistance. In contrast, elevated carboxylated osteocalcin and total osteocalcin were associated with lower insulin resistance, which supports a potential link between skeletal physiology and insulin resistance in humans. The role of vitamin K status in this association remains unclear and merits further investigation. This trial is registered at clinicaltrials.gov as NCT00183001.
Authors: W C Willett; L Sampson; M J Stampfer; B Rosner; C Bain; J Witschi; C H Hennekens; F E Speizer Journal: Am J Epidemiol Date: 1985-07 Impact factor: 4.897
Authors: M Kyla Shea; Gerard E Dallal; Bess Dawson-Hughes; José M Ordovas; Christopher J O'Donnell; Caren M Gundberg; James W Peterson; Sarah L Booth Journal: Am J Clin Nutr Date: 2008-08 Impact factor: 7.045
Authors: Sarah L Booth; Gerard Dallal; M Kyla Shea; Caren Gundberg; James W Peterson; Bess Dawson-Hughes Journal: J Clin Endocrinol Metab Date: 2008-02-05 Impact factor: 5.958
Authors: E Lerchbaum; V Schwetz; S Pilz; T B Grammer; M Look; B O Boehm; B Obermayer-Pietsch; W März Journal: Osteoporos Int Date: 2012-07-10 Impact factor: 4.507
Authors: Norman K Pollock; Paul J Bernard; Karl Wenger; Sudipta Misra; Barbara A Gower; Jerry D Allison; Haidong Zhu; Catherine L Davis Journal: J Bone Miner Res Date: 2010-07-16 Impact factor: 6.741
Authors: Barbara A Gower; Norman K Pollock; Krista Casazza; Thomas L Clemens; Laura Lee Goree; Wesley M Granger Journal: J Clin Endocrinol Metab Date: 2013-04-24 Impact factor: 5.958
Authors: Anna Prats-Puig; Marta Mas-Parareda; Elena Riera-Pérez; Dolors González-Forcadell; Concepció Mier; Montserrat Mallol-Guisset; Marta Díaz; Judit Bassols; Francis de Zegher; Lourdes Ibáñez; Abel López-Bermejo Journal: Diabetes Care Date: 2009-12-15 Impact factor: 19.112